Mineralys Therapeutics, Common Stock Price To Sales
| MLYS Stock | 13.03 0.64 4.68% |
Fundamental analysis of Mineralys Therapeutics, allows traders to better anticipate movements in Mineralys Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year |
Mineralys | Price To Sales | Build AI portfolio with Mineralys Stock |
Mineralys Therapeutics, Common Company Price To Sales Analysis
Mineralys Therapeutics,'s Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Mineralys Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Mineralys Therapeutics, is extremely important. It helps to project a fair market value of Mineralys Stock properly, considering its historical fundamentals such as Price To Sales. Since Mineralys Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mineralys Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mineralys Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Mineralys Therapeutics, Common has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Mineralys Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in price to sales category among its peers.
Mineralys Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 547.27 M | ||||
| Shares Outstanding | 65.18 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 98.72 % | ||||
| Number Of Shares Shorted | 7.87 M | ||||
| Price To Book | 2.61 X | ||||
| EBITDA | (177.77 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 5.26 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 8.76 X | ||||
| Earnings Per Share | (3.75) X | ||||
| Target Price | 36.25 | ||||
| Number Of Employees | 51 | ||||
| Beta | -0.31 | ||||
| Market Capitalization | 890.95 M | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
| Net Asset | 205.9 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.